NO306113B1 - Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler - Google Patents

Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler

Info

Publication number
NO306113B1
NO306113B1 NO954458A NO954458A NO306113B1 NO 306113 B1 NO306113 B1 NO 306113B1 NO 954458 A NO954458 A NO 954458A NO 954458 A NO954458 A NO 954458A NO 306113 B1 NO306113 B1 NO 306113B1
Authority
NO
Norway
Prior art keywords
compounds
drugs
manufacture
receptor antagonists
pharmaceutical preparations
Prior art date
Application number
NO954458A
Other languages
English (en)
Norwegian (no)
Other versions
NO954458D0 (no
NO954458L (no
Inventor
Joachim Gante
Horst Juraszyk
Peter Raddatz
Hanns Wurziger
Sabine Bernotat-Danielowski
Guido Melzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO954458D0 publication Critical patent/NO954458D0/no
Publication of NO954458L publication Critical patent/NO954458L/no
Publication of NO306113B1 publication Critical patent/NO306113B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO954458A 1994-11-08 1995-11-07 Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler NO306113B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4439846A DE4439846A1 (de) 1994-11-08 1994-11-08 Adhäsionsrezeptor-Antagonisten

Publications (3)

Publication Number Publication Date
NO954458D0 NO954458D0 (no) 1995-11-07
NO954458L NO954458L (no) 1996-05-09
NO306113B1 true NO306113B1 (no) 1999-09-20

Family

ID=6532768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954458A NO306113B1 (no) 1994-11-08 1995-11-07 Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler

Country Status (22)

Country Link
US (1) US5776937A (ru)
EP (1) EP0711770A1 (ru)
JP (1) JPH08208629A (ru)
KR (1) KR100384978B1 (ru)
CN (1) CN1069640C (ru)
AR (1) AR002245A1 (ru)
AU (1) AU704184B2 (ru)
BR (1) BR9505109A (ru)
CA (1) CA2162223A1 (ru)
CO (1) CO4520229A1 (ru)
CZ (1) CZ291049B6 (ru)
DE (1) DE4439846A1 (ru)
FI (1) FI955351A (ru)
HU (1) HU217085B (ru)
NO (1) NO306113B1 (ru)
PL (1) PL183595B1 (ru)
RU (1) RU2155762C2 (ru)
SK (1) SK281815B6 (ru)
TR (1) TR199501389A2 (ru)
TW (1) TW316903B (ru)
UA (1) UA41928C2 (ru)
ZA (1) ZA959434B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
AU2713500A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2002535680A (ja) 1999-01-27 2002-10-22 ファルマシア・アンド・アップジョン・カンパニー 延長因子p活性モジュレーターのアッセイ方法
AU2003275480A1 (en) * 2002-10-07 2004-05-04 Smithkline Beecham Corporation Compounds
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
IN2015DN00961A (ru) * 2012-10-29 2015-06-12 Hoffmann La Roche
CN104230915B (zh) * 2014-08-29 2016-08-17 南京大学 含噻唑烷二酮的苯基哌嗪衍生物及其制备方法与用途
JP2020527133A (ja) 2017-06-20 2020-09-03 インブリア ファーマシューティカルズ, インコーポレイテッド 心臓代謝の効率を高めるための組成物および方法
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
DE4405633A1 (de) * 1993-05-01 1994-11-03 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III

Also Published As

Publication number Publication date
CZ288895A3 (en) 1996-06-12
CA2162223A1 (en) 1996-05-09
NO954458D0 (no) 1995-11-07
TW316903B (ru) 1997-10-01
KR960017663A (ko) 1996-06-17
CZ291049B6 (cs) 2002-12-11
AU704184B2 (en) 1999-04-15
KR100384978B1 (ko) 2003-09-02
FI955351A (fi) 1996-05-09
RU2155762C2 (ru) 2000-09-10
UA41928C2 (ru) 2001-10-15
HUT76052A (en) 1997-06-30
SK281815B6 (sk) 2001-08-06
EP0711770A1 (de) 1996-05-15
DE4439846A1 (de) 1996-05-09
AU3661895A (en) 1996-05-23
ZA959434B (en) 1996-05-15
PL311257A1 (en) 1996-05-13
PL183595B1 (pl) 2002-06-28
JPH08208629A (ja) 1996-08-13
CN1069640C (zh) 2001-08-15
TR199501389A2 (tr) 1996-07-21
CO4520229A1 (es) 1997-10-15
US5776937A (en) 1998-07-07
HU217085B (hu) 1999-11-29
NO954458L (no) 1996-05-09
FI955351A0 (fi) 1995-11-07
AR002245A1 (es) 1998-03-11
BR9505109A (pt) 1997-09-09
SK136895A3 (en) 1996-06-05
CN1132201A (zh) 1996-10-02
HU9503191D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
NO305906B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
NO305907B1 (no) Forbindelser, forbindelser for bekjempelse av sykdommer, legemidler som endotelinreseptorantagonist, farmasöytiske preparater samt anvendelse av slike forbindelser til fremstilling av legemidler
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
HUP0100266A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing the compounds and their preparations
NO308296B1 (no) Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel
NO903925L (no) Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler.
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
NO965377D0 (no) Indolinonforbindelser samt farmasöytiske preparater inneholdende forbindelsene
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
FI943570A0 (fi) 1-bentseenisulfonyyli-1,3-dihydroindol-2-onijohdannaisia, niiden valmistus ja niitä sisältäviä lääkeaineita
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
NO305948B1 (no) Basisk substituerte benzolguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum samt medikament inneholdende forbindelsen
NO306060B1 (no) Substituerte kanelsyreguanidider, deres anvendelse samt medikamenter inneholdende guanididene
BR9811582B1 (pt) compostos derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, medicamento e composição farmacêutica contendo os mesmos.
DK13089A (da) Substituerede 5,6,7,8-tetrahydro-4h-thieno-(2,3-d)azepin-forbindelser, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
NO306347B1 (no) Eleutherobin og analoger av denne, anvendelse av forbindelsen samt farmasöytisk preparat inneholdende denne
NO305836B1 (no) Oksazolidin-2-on-forbindelser, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
NO305793B1 (no) 4-aminobenzoylguanidiner, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
DK469189D0 (da) Substituerede thienopyraner, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
NO985171L (no) Sulfonamidsubstituerte kondenserte 5-ringforbindelser, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene
NO306993B1 (no) Piperidinylmetyloksyzolidin-2-on-derivater, farmasoeytiske preparater som inneholder slike, samt anvendelse av forbindelsene til fremstilling av legemidler
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
NO305834B1 (no) 4-merkaptobenzoylguanidiner, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
HUP0004292A3 (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees